Warnings and precautions to be aware of prior to taking Neulasta include the following:
Neulasta has not been adequately studied for collecting stem cells for transplantation and is not approved for this use. Also, it has not been approved for use in people undergoing radiation.
Very rarely, Neulasta may cause enlargement and rupture of the spleen. Tell your healthcare provider if you have symptoms of an enlarged spleen, such as upper abdominal or shoulder pain.
Theoretically, Neulasta can cause adult respiratory distress syndrome (ARDS), a lung problem that can quickly become fatal. Tell your healthcare provider immediately if you develop any breathing problems.
Neulasta can make sickle cell anemia worse. If you have sickle cell anemia, make sure your healthcare provider has specialty training or experience in the treatment of sickle cell anemia before you take Neulasta.
If Neulasta is taken any time within 14 days before chemotherapy until 24 hours after chemotherapy, your risk of infection can actually increase. Usually, Neulasta is given the day after chemotherapy (at least 24 hours afterwards).
Neulasta stimulates the growth of cells. There is a possibility that it may stimulate the growth of cancer cells.
Neulasta is not approved for use in people with myeloid cancers. There is a possibility that Neulasta may stimulate the growth of such cancers.
Neulasta is considered a pregnancy Category C medication. This means that it may not be safe for use during pregnancy. Talk to your healthcare provider about the risks and benefits of using the drug during pregnancy (see Neulasta and Pregnancy).
It is not known if Neulasta passes through breast milk. Therefore, if you are breastfeeding or plan to start, discuss this with your healthcare provider prior to taking the drug (see Neulasta and Breastfeeding).
Previous
Add this article to your Favorites
Email this article
Print